The US Food and Drug Administration (FDA) has issued guidance that will make it easier for harm reduction programs to distribute the opioid-reversal drug naloxone.
The new guidance exempts harm reduction programs from certain requirements of the drug supply chain security act for the distribution of FDA-approved naloxone products during the opioid public health crisis.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.